STATE COLLEGE, Pa., Aug. 13, 2019 /PRNewswire-PRWeb/ -- INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, announced the appointment of Mark McLoughlin to the Company's Board of Directors. Mark brings four decades of healthcare industry experience to the Board.
Mark McLoughlin will lend his healthcare expertise and extensive background in laboratory and scientific products manufacturing, distribution, and tactical marketing to the INDIGO Biosciences Board of Directors, which has helped lead the company to great success throughout the years. "It is a very exciting time to join the INDIGO Board of Directors," said Mr. McLouglin. "INDIGO has a terrific team and portfolio of innovative solutions focused on helping customers with their critical scientific decision-making process, and I'm looking forward to assisting the team s they work to bring these assets to an even wider audience."
Most recently, Mr. McLoughlin served as Executive Vice President for Avantor (formerly VWR International) and Senior Vice President and President of the company's Americas laboratory and distribution services from 2012 to 2018. During his tenure as President for VWR, Mr. McLoughlin was responsible for the profit and loss management of the Americas $3 billion manufacturing, distribution, and services business. He remained directly involved in multiple strategic acquisitions and led the integration of these businesses into the Americas portfolio. Prior to his role as President, Mr. McLoughlin led the category management function for VWR while also leading additional strategic and tactical marketing functions.
Mr. McLoughlin held several senior-level positions for five years at Cardinal Health before his work at VWR, filling the role of Senior Vice President of the scientific products distribution business unit in the acute care laboratory market. He completed his tenure at Cardinal Health based in Rolle, Switzerland, as Senior Vice President and Chief Marketing Officer for the manufacturing business, during which time he was responsible for all geographies outside the United States.
Earlier in his career, Mr. McLoughlin led the global critical care manufacturing business unit for Mallinckrodt prior to its acquisition by Tyco. In his five years at Mallinckrodt, he also led commercial and marketing functions, including the establishment of the company's corporate accounts function. From 1978 to 1996, Mr. McLoughlin held various commercial and leadership roles at American Hospital Supply Corporation and Baxter Healthcare.
"Mr. McLoughlin brings a unique perspective to INDIGO's Board of Directors," said Fred Marroni, CEO of INDIGO Biosciences. "His passion for INDIGO's mission is clear, and we're excited to have his talents and leadership in manufacturing and marketing supplement the extensive experience of our Board."
About INDIGO Biosciences, Inc.
INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and in vitro toxicology solutions that accelerate scientific decision-making. INDIGO supplements the world's largest portfolio of nuclear receptor kits and services and in vitro toxicology solutions with greater results readability, reproducibility, and faster turnaround times. Our solutions, plus supportive team and reliable science and platforms aim to reduce the time, cost, and risk associated with the discovery process. Learn more at http://www.indigobiosciences.com.
SOURCE INDIGO Biosciences
Share this article